Go to
current issue
-
Limping into oblivion Lancet Neurol. (IF 48.0) Pub Date : 2023-09-21 Eelco Wijdicks, Hugo Botha
Abstract not available
-
Long-term risk of cardiovascular disease after traumatic brain injury: screening and prevention Lancet Neurol. (IF 48.0) Pub Date : 2023-09-20 Saef Izzy, Rachel Grashow, Farid Radmanesh, Patrick Chen, Herman Taylor, Rita Formisano, Fiona Wilson, Meagan Wasfy, Aaron Baggish, Ross Zafonte
Traumatic brain injury (TBI) is highly prevalent among individuals participating in contact sports, military personnel, and in the general population. Although it is well known that brain injury can cause neurological and psychiatric complications, evidence from studies on individuals exposed to a single or repetitive brain injuries suggests an understudied association between TBI and the risk of developing
-
The search for treatments for inclusion body myositis Lancet Neurol. (IF 48.0) Pub Date : 2023-09-20 Marianne de Visser, Jan De Bleecker
Abstract not available
-
Beyond the modular brain | Luiz Pessoa, The Entangled Brain: How Perception, Cognition, and Emotion Are Woven Together, MIT Press (2022), p. 230, US$40·00, ISBN: 9780262544603 Lancet Neurol. (IF 48.0) Pub Date : 2023-09-20 Robert Stirrups
Abstract not available
-
Prevention of perioperative stroke in patients undergoing non-cardiac surgery Lancet Neurol. (IF 48.0) Pub Date : 2023-09-20 Maura Marcucci, Matthew T V Chan, Eric E Smith, Anthony R Absalom, P J Devereaux
About 300 million adults undergo non-cardiac surgery annually. Although, in this setting, the incidence of perioperative stroke is low, the absolute number of patients experiencing a stroke is substantial. Furthermore, most patients with this complication will die or end up with severe disability. Covert brain infarctions are more frequent than overt strokes and are associated with postoperative delirium
-
Sustainable development demands brain health Lancet Neurol. (IF 48.0) Pub Date : 2023-09-18
Abstract not available
-
Tamoxifen in children with Duchenne muscular dystrophy Lancet Neurol. (IF 48.0) Pub Date : 2023-09-20 Laurent Servais
Abstract not available
-
Combining cognitive interventions in multiple sclerosis Lancet Neurol. (IF 48.0) Pub Date : 2023-09-20 Amit Lampit, Carsten Finke
Abstract not available
-
Cardiovascular disease after traumatic brain injury: the heart of the matter Lancet Neurol. (IF 48.0) Pub Date : 2023-09-20 Kristen Dams-O'Connor
Abstract not available
-
A genetic basis for the severity of multiple sclerosis Lancet Neurol. (IF 48.0) Pub Date : 2023-09-20 Vilija G Jokubaitis, Helmut Butzkueven
Abstract not available
-
Nitrous oxide and its neurological harms Lancet Neurol. (IF 48.0) Pub Date : 2023-09-20 Alvar Paris, Devan Mair, Safiya Zaloum, Barbara Onen, Alastair J Noyce
Abstract not available
-
Multifaceted dynamics of sex and gender in neurological research Lancet Neurol. (IF 48.0) Pub Date : 2023-09-20 Linda Al-Hassany, Antoinette MaassenVanDenBrink
Abstract not available
-
The EyeVu Consortium for global neurosurgery Lancet Neurol. (IF 48.0) Pub Date : 2023-09-20 Brandon G Smith, Lekaashree Rambabu, Angelos G Kolias, Peter J Hutchinson, Tom Bashford
Abstract not available
-
Correction to Lancet Neurol 2023; 22: 383–94 Lancet Neurol. (IF 48.0) Pub Date : 2023-09-20
Abstract not available
-
Messoud Ashina: pioneering advances in headache research Lancet Neurol. (IF 48.0) Pub Date : 2023-09-20 Jules Morgan
Abstract not available
-
-
Promoting global equality in neuroscience: BioRTC Lancet Neurol. (IF 48.0) Pub Date : 2023-09-20 Mahmoud Maina
Abstract not available
-
Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet Neurol. (IF 48.0) Pub Date : 2023-09-20 Bettina C Henzi, Simone Schmidt, Sara Nagy, Daniela Rubino-Nacht, Sabine Schaedelin, Niveditha Putananickal, Georgia Stimpson
Background Drug repurposing could provide novel treatment options for Duchenne muscular dystrophy. Because tamoxifen—an oestrogen receptor regulator—reduced signs of muscular pathology in a Duchenne muscular dystrophy mouse model, we aimed to assess the safety and efficacy of tamoxifen in humans as an adjunct to corticosteroid therapy over a period of 48 weeks. Methods We did a multicentre, randomised
-
Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial Lancet Neurol. (IF 48.0) Pub Date : 2023-09-20 Pedro M Machado, Michael P McDermott, Thomas Blaettler, Claus Sundgreen, Anthony A Amato, Emma Ciafaloni, Miriam Freimer, Summer B Gibson, Sarah M Jones, Todd D Levine, Thomas E Lloyd, Tahseen Mozaffar, Aziz I Shaibani, Matthew Wicklund, Anders Rosholm, Tim Dehli Carstensen, Karen Bonefeld, Anders Nørkær Jørgensen, Karina Phonekeo, Andrew J Heim, Dolapo Anifowoshe
Background Inclusion body myositis is the most common progressive muscle wasting disease in people older than 50 years, with no effective drug treatment. Arimoclomol is an oral co-inducer of the cellular heat shock response that was safe and well-tolerated in a pilot study of inclusion body myositis, reduced key pathological markers of inclusion body myositis in two in-vitro models representing degenerative
-
Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis (CogEx): a randomised, blinded, sham-controlled trial Lancet Neurol. (IF 48.0) Pub Date : 2023-09-20 Anthony Feinstein, Maria Pia Amato, Giampaolo Brichetto, Jeremy Chataway, Nancy D Chiaravalloti, Gary Cutter, Ulrik Dalgas, John DeLuca, Rachel Farrell, Peter Feys, Massimo Filippi, Jennifer Freeman, Matilde Inglese, Cecilia Meza, Robert W Motl, Maria A Rocca, Brian M Sandroff, Amber Salter
Background Cognitive dysfunction in people with relapsing-remitting multiple sclerosis can improve with cognitive rehabilitation or exercise. Similar effects have not been clearly shown in people with progressive multiple sclerosis. We aimed to investigate the individual and synergistic effects of cognitive rehabilitation and exercise in patients with progressive multiple sclerosis. Methods CogEx was
-
Migraine in older adults Lancet Neurol. (IF 48.0) Pub Date : 2023-09-14 Sarah Sonja Hugger, Thien Phu Do, Håkan Ashina, Maria Teresa Goicochea, Bronwyn Jenkins, Simona Sacco, Mi Ji Lee, K C Brennan, Faisal Mohammad Amin, Timothy J Steiner, Messoud Ashina
Migraine is an evolving, and sometimes lifelong disorder. The prevalence of episodic migraine peaks among individuals aged in their late 30s, implying a tendency for the disorder to remit with increasing age thereafter, whereas chronic migraine is more likely to persist into later life. Diagnosis and treatment of migraine in older adults, defined as individuals aged 60 years or older, is rendered more
-
Correction to Lancet Neurol 2023; 22: 303–11 Lancet Neurol. (IF 48.0) Pub Date : 2023-09-01
Abstract not available
-
The Neurological Pupil index for outcome prognostication in people with acute brain injury (ORANGE): a prospective, observational, multicentre cohort study Lancet Neurol. (IF 48.0) Pub Date : 2023-08-28 Mauro Oddo, Fabio S Taccone, Matteo Petrosino, Rafael Badenes, Aaron Blandino-Ortiz, Pierre Bouzat, Anselmo Caricato, Randall M Chesnut, Anders C Feyling, Nawfel Ben-Hamouda, J Claude Hemphill, Julia Koehn, Frank Rasulo, Jose I Suarez, Francesca Elli, Alessia Vargiolu, Paola Rebora, Stefania Galimberti, Giuseppe Citerio, , Ruihao Wang
Background Improving the prognostication of acute brain injury is a key element of critical care. Standard assessment includes pupillary light reactivity testing with a hand-held light source, but findings are interpreted subjectively; automated pupillometry might be more precise and reproducible. We aimed to assess the association of the Neurological Pupil index (NPi)—a quantitative measure of pupillary
-
The prognostic potential of pupillometry in patients with acute brain injury Lancet Neurol. (IF 48.0) Pub Date : 2023-08-28 Charlene J Ong
Abstract not available
-
Correction to Lancet Neurol 2023; 22: 476–84 Lancet Neurol. (IF 48.0) Pub Date : 2023-08-25
Abstract not available
-
Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study Lancet Neurol. (IF 48.0) Pub Date : 2023-08-23 Mie Rizig, Sara Bandres-Ciga, Mary B Makarious, Oluwadamilola Omolara Ojo, Peter Wild Crea, Oladunni Victoria Abiodun, Kristin S Levine, Sani Atta Abubakar, Charles Obiora Achoru, Dan Vitale, Olaleye Akinmola Adeniji, Osigwe Paul Agabi, Mathew J Koretsky, Uchechi Agulanna, Deborah A Hall, Rufus Olusola Akinyemi, Tao Xie, Mohammed Wulgo Ali, Ejaz A Shamim, Ifeyinwa Ani-Osheku, Zih-Hua Fang
Background An understanding of the genetic mechanisms underlying diseases in ancestrally diverse populations is an important step towards development of targeted treatments. Research in African and African admixed populations can enable mapping of complex traits, because of their genetic diversity, extensive population substructure, and distinct linkage disequilibrium patterns. We aimed to do a comprehensive
-
Brain health, disability, and the need for broader thinking Lancet Neurol. (IF 48.0) Pub Date : 2023-08-16
Abstract not available
-
Prehospital triage in acute stroke: which questions to ask? Lancet Neurol. (IF 48.0) Pub Date : 2023-08-16 Johanna M Ospel, Mayank Goyal
Abstract not available
-
Genome sequencing for the fast diagnosis of early-onset epilepsies Lancet Neurol. (IF 48.0) Pub Date : 2023-08-16 Katrine M Johannesen, Rikke S M⊘ller
Abstract not available
-
Diagnosis of post-stroke dysphagia: towards better treatment Lancet Neurol. (IF 48.0) Pub Date : 2023-08-16 Wuwei Feng
Abstract not available
-
Mar Tintoré, Mar Mediterráneo Lancet Neurol. (IF 48.0) Pub Date : 2023-08-16 Adrian Burton
Abstract not available
-
Changing views of disability Lancet Neurol. (IF 48.0) Pub Date : 2023-08-16 Diana M Cejas
Abstract not available
-
-
Healthy brain in a healthy body | Robert Baloh, Exercise and the Brain: Why Physical Exercise is Essential to Peak Cognitive Health, Springer (2022), p. 213, £24·99, ISBN: 978-3-031-13923-9 Lancet Neurol. (IF 48.0) Pub Date : 2023-08-16 Rui Araújo
Abstract not available
-
Recognising female pioneers in neurology Lancet Neurol. (IF 48.0) Pub Date : 2023-08-16 Lauren Southwell, Helen Reiderman
Abstract not available
-
Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial Lancet Neurol. (IF 48.0) Pub Date : 2023-08-16 Mona Guterud, Helge Fagerheim Bugge, Jo R⊘islien, Jo Kramer-Johansen, Mathias Toft, Hege Ihle-Hansen, Kristi G Bache, Karianne Larsen, Anne-Cathrine Braarud, Else Charlotte Sandset, Maren Ranhoff Hov
Background Timely treatment of acute stroke depends on early identification and triage. Improved methods for recognition of stroke in the prehospital setting are needed. We aimed to assess whether use of the National Institutes of Health Stroke Scale (NIHSS) by paramedics in the ambulance could improve communication with the hospital, augment triage, and enhance diagnostic accuracy of acute stroke
-
Evaluation of the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in infantile epilepsy (Gene-STEPS): an international, multicentre, pilot cohort study Lancet Neurol. (IF 48.0) Pub Date : 2023-08-16 Alissa M D'Gama, Sarah Mulhern, Beth R Sheidley, Fadil Boodhoo, Sarah Buts, Natalie J Chandler, Joanna Cobb, Meredith Curtis, Edward J Higginbotham, Jonathon Holland, Tayyaba Khan, Julia Koh, Nicole S Y Liang, Lyndsey McRae, Sarah E Nesbitt, Brandon T Oby, Ben Paternoster, Alistair Patton, Graham Rose, Elizabeth Scotchman, Amy McTague
Background Most neonatal and infantile-onset epilepsies have presumed genetic aetiologies, and early genetic diagnoses have the potential to inform clinical management and improve outcomes. We therefore aimed to determine the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in this population. Methods We conducted an international, multicentre, cohort study (Gene-STEPS)
-
The assessment of dysphagia after stroke: state of the art and future directions Lancet Neurol. (IF 48.0) Pub Date : 2023-08-16 Bendix Labeit, Emilia Michou, Shaheen Hamdy, Michaela Trapl-Grundschober, Sonja Suntrup-Krueger, Paul Muhle, Philip M Bath, Rainer Dziewas
Dysphagia is a major complication following an acute stroke that affects the majority of patients. Clinically, dysphagia after stroke is associated with increased risk of aspiration pneumonia, malnutrition, mortality, and other adverse functional outcomes. Pathophysiologically, dysphagia after stroke is caused by disruption of an extensive cortical and subcortical swallowing network. The screening
-
Correction to Lancet Neurol 2021; 20: 1027–37 Lancet Neurol. (IF 48.0) Pub Date : 2023-08-09
Abstract not available
-
Correction to Lancet Neurol 2023; 22: 619–31 Lancet Neurol. (IF 48.0) Pub Date : 2023-08-08
Abstract not available
-
Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study Lancet Neurol. (IF 48.0) Pub Date : 2023-07-28 Ahmed Abdelhak, Franziska Petermeier, Pascal Benkert, Sabine Schädelin, Johanna Oechtering, Aleksandra Maleska Maceski, Michael Kabesch, Tobias Geis, Otto Laub, Georg Leipold, Claudio Gobbi, Chiara Zecca, Ari Green, Hayrettin Tumani, Eline Willemse, Heinz Wiendl, Cristina Granziera, Ludwig Kappos, David Leppert, Emmanuelle Waubant, Jens Kuhle
Background Neurological conditions represent an important driver of paediatric disability burden worldwide. Measurement of serum neurofilament light chain (sNfL) concentrations, a specific marker of neuroaxonal injury, has the potential to contribute to the management of children with such conditions. In this context, the European Medicines Agency recently declared age-adjusted reference values for
-
NfL is ready for translation into paediatrics Lancet Neurol. (IF 48.0) Pub Date : 2023-07-28 Simon Thebault, Amit Bar-Or, Brenda Banwell
Abstract not available
-
Secondary stroke prevention: more questions than answers Lancet Neurol. (IF 48.0) Pub Date : 2023-07-25 Coralie English, Emily Ramage
Abstract not available
-
Richard Morris on memory: the 2022 Ferrier Prize Lecture Lancet Neurol. (IF 48.0) Pub Date : 2023-07-25 Hollie Sherwood-Martin
Abstract not available
-
Correction to Lancet Neurol 2023; 22: 494–504 Lancet Neurol. (IF 48.0) Pub Date : 2023-07-20
Abstract not available
-
Time to get serious about the Global Action Plan on dementia Lancet Neurol. (IF 48.0) Pub Date : 2023-07-19
Abstract not available
-
Lessons and future directions for GBA1-targeting therapies Lancet Neurol. (IF 48.0) Pub Date : 2023-07-19
Abstract not available
-
Blocking inhibitors of axon growth after spinal cord injury Lancet Neurol. (IF 48.0) Pub Date : 2023-07-19
Abstract not available
-
Global burden of meningitis and implications for strategy Lancet Neurol. (IF 48.0) Pub Date : 2023-07-19
Abstract not available
-
Fetal exposure to antiseizure medications: reassurance and concerns Lancet Neurol. (IF 48.0) Pub Date : 2023-07-19
Abstract not available
-
Navigating the challenges of diagnosing multiple sclerosis Lancet Neurol. (IF 48.0) Pub Date : 2023-07-19
Abstract not available
-
Peru initiates the IMPACT project Lancet Neurol. (IF 48.0) Pub Date : 2023-07-19
Abstract not available
-
Flora Hammond: teaching us a new song Lancet Neurol. (IF 48.0) Pub Date : 2023-07-19
Abstract not available
-
The microglial hypothesis of multiple sclerosis Lancet Neurol. (IF 48.0) Pub Date : 2023-07-19
Abstract not available
-
-
Climate change and neurology: time to talk and to act Lancet Neurol. (IF 48.0) Pub Date : 2023-07-19
Abstract not available
-
A golden garden for people with rare dementias Lancet Neurol. (IF 48.0) Pub Date : 2023-07-19
Abstract not available
-
Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial Lancet Neurol. (IF 48.0) Pub Date : 2023-07-19
Background Variants in the GBA1 gene, which encodes lysosomal acid glucocerebrosidase, are among the most common genetic risk factors for Parkinson's disease and are associated with faster disease progression. The mechanisms involved are unresolved but might include accumulation of glucosylceramide. Venglustat is a brain-penetrant glucosylceramide synthase inhibitor that, in previous studies, reduced
-
Soluble Nogo-Receptor-Fc decoy (AXER-204) in patients with chronic cervical spinal cord injury in the USA: a first-in-human and randomised clinical trial Lancet Neurol. (IF 48.0) Pub Date : 2023-07-19
Background Spinal cord injury (SCI) causes neural disconnection and persistent neurological deficits, so axon sprouting and plasticity might promote recovery. Soluble Nogo-Receptor-Fc decoy (AXER-204) blocks inhibitors of axon growth and promotes recovery of motor function after SCI in animals. This first-in-human and randomised trial sought to determine primarily the safety and pharmacokinetics of
-
Global, regional, and national burden of meningitis and its aetiologies, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 Lancet Neurol. (IF 48.0) Pub Date : 2023-07-19
Background Although meningitis is largely preventable, it still causes hundreds of thousands of deaths globally each year. WHO set ambitious goals to reduce meningitis cases by 2030, and assessing trends in the global meningitis burden can help track progress and identify gaps in achieving these goals. Using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we aimed
更新日期：2023-09-23
Copyright © 2014-2023 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495-2号
京公网安备 11010802027423号
京公网安备 11010802027423号